CJC-1295 and ipamorelin: are they the same kind of peptide?

Why are they often discussed together?

People may encounter these names when researching muscle, recovery, body composition or sleep. CJC-1295 is designed to imitate a signal that asks the pituitary gland to release growth hormone; ipamorelin acts through a different receptor involved in growth-hormone release. The idea of combining them is to influence the same hormone system through different signals. That is a rationale, not evidence that the combination improves those everyday outcomes. Growth hormone is a chemical messenger; a change in its level is not the same thing as a measured improvement in strength, sleep or recovery. Explore the separate CJC-1295 and ipamorelin profiles for their individual studies and limitations.

To understand why “fat burning”, appetite and body-weight claims can mean different things, see the guide to weight-loss peptides and fat.

For the bigger picture, follow the growth-hormone signal and its connection to muscle, fat and sleep. Understand CJC-1295 with DAC, no DAC and the human studies.

For a related question, compare ipamorelin and MK-677: shared signals and different evidence.57

Mechanism is not a scorecard

Two peptides can affect the same biological axis through different receptors and still produce different timing, exposure and downstream effects. A rise in a hormone or biomarker is not the same as improved sleep, recovery, body composition or another patient-important outcome.3

What human evidence can answer

A useful comparison would define the product and route, enrol a relevant population, compare against placebo or standard care and measure outcomes and harms over an appropriate period. Online stack reports usually do not supply those controls or denominators.12

What did the human studies actually compare?

They did not compare these peptides with each other. A 2006 report on long-acting CJC-1295 described two placebo-controlled studies in healthy adults: 42 participants in a single-administration study and 24 in a multiple-administration study. Growth hormone and IGF-1 increased, but the studies did not establish better sleep, strength, recovery or long-term health. The product developer, ConjuChem, supported the research.

A 2014 study of ipamorelin instead enrolled 117 adults after bowel surgery; 114 received study treatment. Its main outcome was how long it took before a solid meal could be tolerated. The median was 25.3 hours with intravenous ipamorelin and 32.6 hours with placebo, but the difference was not statistically significant. The trial did not establish a benefit for that outcome, and it did not test sleep, muscle growth or a combination with CJC-1295.

The FDA’s 2024 briefing reported serious adverse events in 10 of 56 people given ipamorelin and 9 of 58 given placebo. Two people who received ipamorelin died after postoperative complications; whether the drug contributed was unclear. The small study cannot reliably establish the cause of these events or compare uncommon harms. That observation is neither proof of causation nor a risk estimate for other products. Different participants, preparations, routes and outcomes make a ranking of the two peptides—or a claim that their combination is better—impossible from these studies.567

Safety and product quality

FDA materials identify possible immunogenicity, aggregation and peptide-impurity concerns for some compounded peptide routes; CJC-1295 records also describe serious events in limited clinical data. These records are warnings and evidence gaps, not a complete estimate of risk for every possible formulation.124